Roy Blunt
Known title: DirectorCIK: 0001986272
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Southwest updates Rapid Rewards and previews Q3 earnings. Southwest Airlines announced changes to its Rapid Rewards program, adding new elite status tiers and expanding redemption options. The updates aim to enhance member benefits and could influence future revenue streams. Analysts are also looking ahead to the company's upcoming Q3 earnings, focusing on key performance metrics. Additionally, Southwest revealed plans for an Icon Lounge in Nashville slated for 2027, indicating continued investment in premium services.
Transaction History
| THC | ▼ Sell | Open Market | 600 | $158K | 8/5/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,333 | — | 5/22/2026 | View on chart |
| THC | ▼ Sell | Other | 493 | $86K | 5/22/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| LUV | ▲ Buy | Grant | 6,122 | $0 | 5/15/2024 | View on chart |
| THC | ▲ Buy | Grant | 2,798 | $0 | 8/9/2023 | View on chart |
| LUV | ▲ Buy | Grant | 5,095 | $0 | 8/2/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets
Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.